Exchange: NASDAQ·Updated 04:26 PM EST
OCGN logo

OCGN Ocugen Inc

$0.7393
$0.0175
(2.31%)
Today
Closed $0.7392
$0.0001
(0.01%)
After Hours
Reported EarningsNov 4
Mkt Cap$256.75M
Vol5.82M

About OCGN

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
43

Bearish Sentiment

How do you feel about OCGN?

TheUrbanFarmer
$OCGN amazing how these donkeys have gone on and on for months now, claiming to be long term shareholders from the COVID peak, obnoxiously spamming shareholders to vote no, with main focus on management compensation/Shankar’s awards. You would think a real investor, let alone a 6 year holder, would have mentioned back then or knew by now that shareholders voted on management’s compensation only awarded after milestones are met back in June this year, just like they have every single year since the company went public…😂🫏💀 Anyways, the vote will pass in December, flipping our books to bullish, along with Bahamas full approval and our first commercial patient being dosed. Goodbye to the days of absurdities and the clowns that know absolutely nothing at all about the company spamming the board, hello to the days of revenue and growth.🍻👇
3
30
Madpatsy
$OCGN Looks to close under $1 for 30 consecutive days on Wednesday 11/18/26. They will be issued a deficiency notice. Ocugen must file a Form 8-K with the SEC and issue a press release within four business days of receiving the formal notice from Nasdaq They will get an initial +180 Days to Cure = Mid-May 2027. Really a Nothing burger if you believe in positive OCU400 Phase 3 Data in March or Bahama EAP starting in Dec/Jan/Feb/Mar/Apr. Good time to get cheap shares. Lower avg/etc.
1
28
OcugenInc
Ocugen Chairman, CEO, and Co-Founder Shankar Musunuri, PhD, MBA, sat down with BBC Correspondent James Gallagher at Cell & Gene Leaders Live in London. The discussion highlighted Ocugen’s differentiated gene therapy platform and its potential to address vision loss across a broader patient population, regardless of the underlying genetic mutation. Ocugen combines a broad platform with a focus on diseases affecting large patient populations to redefine the commercial opportunity for potential one-time treatments with lifelong benefits. $OCGN
1
31
TheUrbanFarmer
$OCGN People see Celairis isn’t a giant, lacks doctors or labs, and assume they can’t do anything. Reality is, a guy with RP walks into an ophthalmology office, doc says there’s an approved treatment, and he goes to a local surgeon to get dosed. These aren’t development partnerships, they’re licensing deals. Ocugen retains control/sole manufacturing rights. Celairis gets OCU400 approved. The question isn’t whether Celairis can manufacture or perform surgery. It’s whether they can get us approved. Their CEO spent 11 years at Novartis as Country President for Australia/New Zealand, then ran Australia’s largest pharma company. I’d say he’s exactly who we need. Ocugen isn’t selling out to BP. They know what they own, have commercial supply ready, and their drug uses existing surgical techniques. They’re expanding globally. Nothing more, nothing less. The outcome is thousands of million dollar checks coming in globally for Ocugen to collect for the next 10+ years. 🍻
1
34
mrpauley
$OCGN testing our patience and sanity. I'm gonna walk away for a few days, see you all soon!
20
Madpatsy
$OCGN For the Panickers. 10/8/26 - 1st Day under 11/18/26 - 30th Day under 11/23/26 - My Money Clears Schwab -> buy more. 11/24/26 - OCGN Must PR Deficiency within 4 Business Days 12/22/26 - Shareholder Vote 02/28/27 - OCU400 Bahama Mama dose* $$$ 03/30/27 - OCU400 Topline Data "by" End of Q1 05/07/27 - # 1Q Business Meeting - Bahama $$ :) 05/15/27 - 1st Date Investor Eligible to Convert^ 05/17/27 - 180 Day - "1st" Deadline OCGN eligible for 2nd. 11/13/27 - 2nd 180 Days "Final" Deadline" * OCGN Bahama EOY potential +2 month to be Conservative. # ~1Q Meeting historically ^Investors won't convert if substantially under $2.67 conversion price. LOTS OF TIME with ALL MEGA CATALYSTS
17
mrpauley
$OCGN i called it dropping to 89 cents in it's first hour. i think it will hold here but if it goes down to 85 to 86, don't freak out. i think these are the last weeks we will be under a dollar.
1
22
Tainted_Love
$OCGN When u are playing the end game … these prices don’t bother you , u welcome them !!! #trueblessing
17
WayLoSellHi
$OCGN Well we're not in the air travel biz nor the AI biz nor the data center build out biz & Shank isn't nailing a Chinese spy 😉 All we're trying to do is get our game changing P3 OCU400 to mkt along with the rest of our pipe to give hope where there's no hope😇 Hope isn't the word to use in vesting but I hope sooner than later all the shorts & naysayers get F'ng nuked 🔥
1
18
Mart41
$OCGN 🚀 A major pharmaceutical company typically waits for final clinical results (expected in Q1 2027 for OCU400) before committing to lucrative Western markets. The best-positioned players are: • Novartis. A global pioneer in ocular gene therapy thanks to Luxturna (the first approved gene therapy for an inherited retinal disease), the Swiss group already possesses all the necessary commercial and surgical infrastructure. OCU400's "gene-agnostic" approach (effective regardless of the genetic mutation) would complement its portfolio. • Roche. A massive leader in ophthalmology with Vabysmo and owner of Spark Therapeutics (the original developer of Luxturna), Roche is actively seeking new growth drivers in rare retinal diseases and geographic atrophy (targeted by Ocugen's OCU410 candidate). • Johnson & Johnson. The US group invests heavily in gene therapies for retinitis pigmentosa (notably through its partnership with MeiraGTx).
1
9
Kickstarterx10
$OCGN Please don’t root for a Phase 3 failure. Whether you’re bullish or bearish, there are patients and families desperately hoping for a life-changing treatment. We should ALL hope for a successful trial. Patients deserve that hope and a better future. You can absolutely hold management accountable, demand better leadership, and call for Shankar to STEP DOWN! But never wish for the science to fail. Patients come FIRST!
15
Bedtimereminder
$OCGN I believe the December 22 vote could be the first genuinely positive catalyst for $OCGN in the near term. A YES vote would give the company a much stronger foundation to keep executing its plans and move its pipeline forward. Let’s be realistic: some dilution over the next 12 months is probably unavoidable. Bringing products to market takes capital. That’s the reality. But without funding, how can the company move forward and unlock its potential? Recent news has been encouraging, but so far it hasn’t been enough to turn the share price around. The market needs to see that OCGN has the financial flexibility to execute. A YES vote could be the first step toward that. Vote YES. Let the company execute. Welcome to Venus! 🚀
1
8
ignaciobis
$OCGN OCUGEN – Key Updates from the November 12, 2026 Conference OCU400: Four-year follow-up data will be released before the Phase 3 topline results (Q1 2027). Expanded Access Program: Patients treated represent 15 different genetic mutations. Shankar mentioned positive feedback from investigators, although complete clinical data have not yet been published. FDA: Shankar outlined a potential FDA approval and commercial launch of OCU400 in Q4 2027, subject to regulatory timelines. Commercialization: Ocugen plans to expand its current network of 30–35 treatment centers to 50–100 specialized centers. Financing: Following Phase 3 results, the company is considering royalty-based financing, equity financing, and other options, prioritizing non-dilutive alternatives. Overall: Positive updates regarding clinical development and commercial readiness, but no new signed agreements or definitive clinical results were announced.
1
15
phsc0015
$OCGN keep cool!! Shorts running out of money and manipulating the SP. They cant hold it down forever!!
1
15
LittleDerwin
$OCGN Jeez my portfolio is a dumpster fire today - at least it’s beer o’clock in the UK. Keep on trucking guys 🍻
16
calbucs
$OCGN Back to $1.50 range , shortie won’t be able to hold it down much longer . Too many positives in the last month to stay this low .
16
Djtrush
$OCGN My wife’s boyfriend said I can buy more shares if I sleep in the shed tonight whilst his buddy’s come over for the game.
15
Uebikus
$OCGN Oh, that looks really good. The green line is the target for the pattern if $OCGN breaks out upward through the triangle.
15
sidsai
$OCGN correct, our CEO more ethical than most. Better than losing 50% of market cap in a month for the most valuable company on earth due to personal urges.
1
12
dgiudice
$OCGN ONE of every THREE shares is shorted for Ocugen. We still don't know who, but there's a ton of people who are gonna take a shot to the face very soon. I don't know, but Ocugen has been doing a lot of work for a company with products that are scams. SCAMS???
15

Advertisement|Remove ads.